Welcome to our dedicated page for ZEO ScientifiX news (Ticker: ZEOX), a resource for investors and traders seeking the latest updates and insights on ZEO ScientifiX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEO ScientifiX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEO ScientifiX's position in the market.
ZEO ScientifiX (OTCQB:ZEOX) has launched ZEO Xperience, a three-day immersive regenerative medicine educational event for licensed healthcare professionals, to be held October 23-25, 2026, at the newly reimagined Pier Sixty-Six Resort in Fort Lauderdale, Florida.
The inaugural ZEO Xperience combines evidence-based education in regenerative biologics, hands-on clinical training, practice growth strategies, and exposure to emerging technologies. Programming is organized into three themed days: Science & Innovation, Clinical Training & Practice Growth, and a Biohacking Experience focused on performance optimization and wellness technologies. Attendance is intentionally limited to foster interaction and collaboration, and registration is now open via the company’s website.
ZEO ScientifiX (OTCQB:ZEOX) highlights its role in South Florida’s biotechnology ecosystem from its base at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida. The company focuses on regenerative biologic research, development, manufacturing, and physician education as interest in regenerative medicine grows across multiple specialties.
According to ZEO ScientifiX, its strategy centers on building a stronger bridge between scientific advancement and clinical practice through physician Master Classes, webinars, scientific programming, professional collaborations, and an expanded Medical Advisory Board. The company plans to continue expanding scientific and educational initiatives and deepen relationships across the medical community to support responsible advancement of regenerative medicine in Florida’s emerging life sciences hub.
ZEO ScientifiX (OTCQB:ZEOX) reported sharp revenue growth for the quarter and six months ended April 30, 2026. Quarterly revenue rose 124.6% to $2.58 million, while six-month revenue increased 79.9% to $4.03 million, mainly from allogenic biologic products.
The company maintained approximately 80% gross margins for the six-month periods in 2026 and 2025 and reduced its six-month net loss to about $1.0 million from $2.6 million a year earlier, reflecting expanding demand, higher physician adoption, and broader awareness of its regenerative biologics portfolio.
ZEO ScientifiX (OTCQB:ZEOX) will host a live virtual educational webinar for healthcare professionals titled “One Year Later, Three States Stronger: The Southeast Regen Revolution” on July 22, 2026 at 6:45 p.m. ET.
The session will review Florida’s first year under its stem cell law, discuss new laws in Tennessee and Georgia, and offer scientific, medical, and regulatory perspectives on expanding regenerative medicine access across the Southeast.
ZEO ScientifiX (OTCQB:ZEOX) supported a 10-day pediatric burn reconstruction mission in Cusco, Peru by donating regenerative biologic products used by Medical Advisory Board member Dr. Constantino Mendieta.
The team evaluated about 80 children and performed nearly 40 reconstructive surgeries, aligning with ZEO ScientifiX’s focus on physician-led care and regenerative medicine education.
ZEO ScientifiX (OTCQB:ZEOX) expanded its Medical Advisory Board by adding nine physicians and scientific innovators in regenerative and longevity medicine. The board now spans orthopedics, oncology, longevity, pain management, plastic surgery, and advanced biologic therapies, supporting clinical protocols, product standards, and physician education.
Advisors will guide scientific development, serve as faculty for educational programs such as the Physician-Led Patient Masterclass, and contribute to initiatives including the XPRIZE Healthspan longevity prize competition, where ZEO ScientifiX was selected as a $101 million semi-finalist.
ZEO ScientifiX (OTCQB:ZEOX) launched a Physician-Led Patient Masterclass program on May 27, 2026, to help doctors educate patients on regenerative medicine. The initiative builds on training over 600 physicians across the Southeast in stem cell use for Florida-permitted indications: pain management, wound care, and orthopedics.
The program formalizes a successful Vero Beach pilot led by Dr. Alita Sikora and focuses on physician-hosted events, safety, product sourcing standards, and informed patient decision-making.
ZEO ScientifiX (OTCQB:ZEOX) reported that unaudited monthly sales surpassed $1.0 million in April 2026, the first time it has reached this level. Management views this as a key growth inflection, driven by a newly built internal sales force and physician education masterclass programs supporting regenerative medicine clinics.
ZEO ScientifiX (OTCQB:ZEOX) announced it has trained more than 500 physicians through its one-day monthly Masterclass series, averaging 70+ clinicians per month. The program covers Florida regulatory requirements, evidence-based science, ethical sourcing, manufacturing quality, and operational practice integration.
The Masterclass features legal, Ph.D., and clinical experts, includes a tour of ZEO ScientifiX research facilities, and the next session is scheduled for April 24, 2026 at Nova Southeastern University's Center of Innovation.
ZEO ScientifiX (OTCQB:ZEOX) entered an exclusive memorandum of understanding with Regen Therapy on April 9, 2026, to serve as Regen's core supplier for advanced biologic therapeutics, while Regen partners with Stealth Health to deploy white‑label telemedicine and longevity services across >3,000 clinics and 24,000 practitioners.
The integrated model combines ZEO biologics, Stealth Health prescriber/pharmacy infrastructure, and Metabolic Code® analytics to deliver scalable, clinic‑embedded regenerative and longevity care through cGMP processes.